TYRA (Tyra Biosciences Inc) Earnings per share for the last four quarters

Public company logo of Tyra Biosciences Inc (TYRA)

After assessing the current EPS YoY TTM growth rate on GURU.Markets, we find that -40.50 captures the value of this parameter for Tyra Biosciences, Inc. (TYRA). Growth is hindered by strict FDA oversight and the patent protection of the SNAP platform. Meanwhile, the company attracts leading oncologists through flexible working conditions. The business is fully insulated from global political tensions and logistical disruptions, maintaining a neutral backdrop.

TYRA tyra.bio Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

Tyra Biosciences Inc - analytical breakdowns and key metrics (TYRA)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:Tyra Biosciences (TYRA)
Signature product of Tyra Biosciences

This indicator assesses the dynamics of net income per share over a rolling year, eliminating the volatility of one-time payments by comparing the current TTM period with the corresponding prior period. By analyzing the YoY EPS growth rate over the last 12 months, an investor can gauge the capital management efficiency of Tyra Biosciences, Inc. (TYRA), where in the absence of revenue, the metric reflects only the cash burn rate for R&D.

Competitor analysis for Tyra Biosciences, Inc.

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX